Alpha 2.0
Login Register
» Authors » Daniel C Chambers

Daniel C Chambers

Explore the profile of Daniel C Chambers including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 114
Citations 3085
Followers 0
Related Specialties
Pulmonary Medicine
General Surgery
Cardiology & Vascular Diseases
Top 10 Co-Authors
Josef Stehlik
Wida S Cherikh
Kiran K Khush
Stephanie T Yerkovich
Don Hayes Jr
Andreas Zuckermann
Peter Hopkins
Ian Glaspole
Luciano Potena
Bruno Meiser
Published In
J Heart Lung Transplant
Respirology
Am J Respir Crit Care Med
Chest
Transplantation
Affiliations
Soon will be listed here.
Recent Articles
1.
Primary graft dysfunction, dysbiosis, and innate immune activation after lung transplantation
Stewart A, Chambers D
J Heart Lung Transplant . 2024 Dec; 44(3):435-436. PMID: 39672290
No abstract available.
2.
Trial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients
Dousset L, Chambers D, Webster A, Isbel N, Campbell S, Duarte C, et al.
Trials . 2024 Nov; 25(1):789. PMID: 39578921
Background: Keratinocyte carcinomas such as basal cell carcinomas and squamous cell carcinomas are a major burden affecting morbidity and mortality in solid organ transplant recipients (SOTRs). Best treatment includes frequent...
3.
Toward early prediction of chronic allograft dysfunction using molecular biomarkers
Bell P, Chambers D
J Heart Lung Transplant . 2024 Nov; 44(3):329-330. PMID: 39522623
No abstract available.
4.
Closing the Loop on Diagnostic Testing in Interstitial Lung Disease
Chambers D, Mackintosh J
Chest . 2024 Nov; 166(5):909-910. PMID: 39521536
No abstract available.
5.
Silicosis-Where to from here?
Barnes H, Chambers D
Respirology . 2024 Nov; 29(12):1020-1022. PMID: 39492568
No abstract available.
6.
Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung disease
Li A, Teoh A, Troy L, Glaspole I, Wilsher M, de Boer S, et al.
Thorax . 2024 Sep; 79(11):1024-1032. PMID: 39317451
Background: Lung function testing remains a cornerstone in the assessment and management of interstitial lung disease (ILD) patients. The clinical implications of the Global Lung function Initiative (GLI) reference equations...
7.
Cloaking antibodies are prevalent in complex infection and their removal restores serum killing
Pham A, Tan K, Ledger E, Smith D, Reid D, Burr L, et al.
Front Cell Infect Microbiol . 2024 Aug; 14:1426773. PMID: 39193503
Introduction: The complex encompasses a group of gram-negative opportunistic pathogens that cause chronic lung infections in people with cystic fibrosis. Distinct from other respiratory pathogens, causes a unique clinical disease...
8.
Management of infectious disease syndromes in thoracic organ transplants and mechanical circulatory device recipients: a Delphi panel
Luong M, Nakamachi Y, Silveira F, Morrissey C, Danziger-Isakov L, Verschuuren E, et al.
Transpl Infect Dis . 2024 Feb; 26(3):e14251. PMID: 38351512
Purpose: Antimicrobial misuse contributes to antimicrobial resistance in thoracic transplant (TTx) and mechanical circulatory support (MCS) recipients. This study uses a modified Delphi method to define the expected appropriate antimicrobial...
9.
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
Mackintosh J, Chambers D
Eur Respir J . 2024 Jan; 63(1). PMID: 38237995
No abstract available.
10.
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision
Mackintosh J, Keir G, Troy L, Holland A, Grainge C, Chambers D, et al.
Respirology . 2024 Jan; 29(2):105-135. PMID: 38211978
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA)...